Learn about UCSF’s response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more
UCSF researchers found that mice in which activity of a protein called eIF4E is diminished, either genetically or pharmaceutically, gain only half the weight of other mice, even if all the mice eat a high-fat diet.
Tissue biologist Sarah Knox has long been fascinated with saliva. Just when she begins to doubt whether her singular passion will lead to real-world impact, an old family friend reaches out to her with a problem only she may be able to solve.
UCSF scientists have discovered a new way to control the immune system’s “natural killer” cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection.
Researchers found that patients with a pediatric cancer who were protected under the ACA’s dependent coverage provision were more likely to remain on private insurance for longer durations compared to their older peers who turned 19 before the Act.
Though cancer immunotherapy has become a promising standard-of-care treatment – and in some cases, perhaps a cure – for a wide variety of different cancers, it doesn’t work for everyone, and researchers have increasingly turned their attention to understanding why.
None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, researchers say, as long as the therapies are applied equitably.
A new model of the causes of breast cancer, created by a team led by researchers at UCSF, Genentech and Stanford University, is designed to capture the complex interrelationships between dozens of primary and secondary breast cancer causes and stimulate further research.
UCSF researchers now have reported a new method to design and test cell therapies, one they expect will speed the development of new life-saving treatments not only for cancer, but for other diseases, too.
A future in which precision medicine benefits everyone is not guaranteed. For that to happen, UCSF experts argue, the health care industry must first tackle today’s health disparities, including differences in disease outcomes and access to care based on race, gender, and socioeconomic status.
In a breakthrough with important implications for the future of immunotherapy for breast cancer, UCSF scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.